NN1177

Cat. No.:	HY-P10032
Molecular Formula:	$C_{206}H_{323}N_{51}O_{66}$
Molecular Weight:	4570.07
Sequence:	His-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Tyr-Leu-Glu-Ser-Lys-Arg-Ala-Arg-Glu-Phe-Val-Gln-Trp-Leu-Leu-{Lys(gGlu-gGlu-Ser-Glu-Ser-gGlu-gGlu-C18 diacid)}-Thr-NH2
Sequence Shortening:	H-{Aib}-QGTFTSDLSKYLESKRAREFVQWLL-{Lys(γGlu-γGlu-Ser-Glu-Ser-γGlu-γGlu-C18 diacid)}-T-NH2
Target:	GCGR; GLP Receptor; Cytochrome P450
Pathway:	GPCR/G Protein; Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	NN1177 is a long-acting GLP-1/glucagon receptor co-agonist. NN1177 can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice[1][2].
In Vitro	NN1177 (100 nM, 3 days) reduces CYP3A4 mRNA expression (57.2-71.7%) and activity (18.5-51.5%) in freshly isolated human hepatocytes[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	NN1177 (3 or 5 nmol/kg, s.c.) induces body weight loss, loss of fat mass, and improvement in glucose tolerance in diet-induced obese (DIO) mice[1]. NN1177 (0.75-4 nmol/kg, s.c., once daily, 8 weeks) reduces liver fat and inflammatory and fibrosis relevant biomarkers in C57Bl/6 mice fed a fructose and high fat rich diet (NASH model)[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Simonsen L, et al. Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls. PLoS One. 2022 Mar 4;17(3):e0264974.

[2]. Monfeuga T, et al. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients. Mol Metab. 2023 Dec 7;79:101850.

[3]. Säll C, et al. In vitro CYP450 enzyme down-regulation by GLP-1/glucagon co-agonist does not translate to observed drug-drug interactions in the clinic. Drug Metab Dispos. 2022 Jun 9:DMD-AR-2022-000865.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA